Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 4/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906599 | 1.00 | DPP3 (0.53) | DPP3OPRM1BCHEACEACE2 | |
| SCHEMBL14903356 | 0.97 | DPP3 (0.53) | DPP3OPRM1BCHEACEACE2 | |
| SCHEMBL14906594 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL6879254 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL14903405 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL14906472 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL14906468 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL6880566 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL6879256 | 0.88 | ACE (0.59) | ACEACE2LTA4H | |
| SCHEMBL14903414 | 0.86 | ACE (0.49) | ACEACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2019-03-26 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| EP-2536732-B1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP Z O O (PL) | 2016-10-19 | — | — | EP | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-20130224232-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2013-08-29 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
| WO-2011103524-A2 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP.Z.O.O. (PL) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | DPP3 300/4885OPRM1 1275/4885BCHE 1686/4885 |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | DPP3 300/4885OPRM1 1275/4885BCHE 1686/4885 |
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PNISR, APLNR, VIP | DPP3 300/4885OPRM1 1275/4885BCHE 1686/4885 |
| US-20130224232-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, VIP, APLNR | DPP3 245/4885OPRM1 1208/4885BCHE 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.